# Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)

> **NCT05575167** · — · RECRUITING · sponsor: **424 General Military Hospital** · enrollment: 125 (estimated)

## Conditions studied

- Osteoporosis, Postmenopausal

## Interventions

- **DRUG:** Zoledronate or Alendronate

## Key facts

- **NCT ID:** NCT05575167
- **Lead sponsor:** 424 General Military Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-28
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05575167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05575167, "Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05575167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*